跳至主要内容
临床试验/EUCTR2021-000710-42-NL
EUCTR2021-000710-42-NL进行中(未招募)1 期

The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dose and vaccination timing. A prospective cohort study. - RTX-COVAC

Sint Maartenskliniek0 个研究点目标入组 270 人开始时间: 2021年3月8日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
270

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Rheumatoid arthritis: either 2010 EULAR/ACR RA and/or 1987 ACR RA criteria and/or clinical diagnosis of the treating rheumatologist;
  • Treatment with at least one dose of rituximab (most of the times 200 mg, 500 mg or 1000 mg one or two times, but all dosages are included) in the year prior to the COVID-19 vaccine;
  • Expected to receive a registered COVID-19 vaccine or have received a registered COVID-19 vaccine in the last 6 months;
  • =16 years old and mentally competent;
  • Ability to read and communicate in Dutch.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 170
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 100

排除标准

  • Not eligible (for example allergic to one of vaccine ingredients) or not willing to receive the COVID-19 vaccine;

研究者

相似试验